Diebold Nixdorf Q3 EPS Falls to $0.19 as Charges Bite; New $250M Buyback Authorized
DBD is trading near its 52-week low of $54.48 (4.6% above the low) on elevated volume (4.0× avg).
Summary
Diebold Nixdorf's Q3 revenue rose 5.2% to $994.3M, but net income fell to $6.6M from $41.1M on higher restructuring and a $16.9M impairment, while nine-month operating cash flow turned negative. The board also authorized a new $250.0M buyback.
Key Events · Earnings and Guidance · DBD
-
Q3 Revenue Up 5.2%, Profit Down Sharply
Net sales rose to $994.3M from $945.2M, driven by Retail products up 30.9%, but net income attributable to Diebold Nixdorf fell to $6.6M ($0.19 diluted EPS) from $41.1M ($1.11).
-
Restructuring and Impairment Hit Operating Profit
Operating profit fell to $38.8M from $73.8M as restructuring charges rose to $34.5M from $12.6M and a $16.9M impairment was taken on an unconsolidated Chinese subsidiary.
-
Operating Cash Flow Turns Negative
Nine-month operating cash flow was -$29.3M versus +$83.2M a year ago; cash, equivalents and restricted cash fell to $184.9M from $387.3M at December 31, 2025, after $154.9M of treasury share purchases.
-
New $250.0M Buyback Authorized
On October 28, 2026 the board approved a new $250.0M repurchase program; the prior $200.0M program had $23.5M remaining at September 30, 2026.
Analysis · DBD · Technology
Revenue grew 5.2% to $994.3M on a strong Retail quarter, but the profit line collapsed: net income attributable to Diebold Nixdorf fell to $6.6M from $41.1M a year ago, and operating profit nearly halved to $38.8M from $73.8M as restructuring charges jumped to $34.5M from $12.6M and a $16.9M impairment hit the China subsidiary investment. Cash is the bigger concern: nine-month operating cash flow swung to -$29.3M from +$83.2M, and cash plus short-term investments dropped to $184.9M from $416.4M at year-end, with $154.9M spent on buybacks. Against that backdrop the board authorized a fresh $250.0M repurchase program on October 28, 2026 — aggressive capital return while free cash flow is negative and full-year guidance was just cut in the concurrent 8-K.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 38.5% of the 1020 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DBD was trading at $57.00 on NYSE in the Technology sector, with a market capitalization of approximately $2B. The 52-week trading range was $54.48 to $92.09. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.